\-\ Texto\\:\\ \ \(0\)\
\-\ tsi\\ 279\\ h\\ \\(\\<125\\)\ \(0\)\
\-\ thyrotro\\ bn\\ inh\\ 78\\.7\\ h\\ \\(\\<16\\)\ \(0\)\
\-\ tsh\\ 1\\.98\\ \\(0\\.27\\ \\‚\\Ä\\ì\\ 4\\.2\\)\ \(0\)\
\-\ ft4\\ 1\\.25\\ \\(1\\.01\\ \\‚\\Ä\\ì\\ 1\\.79\\)\ \(0\)\
\-\ per\\ endocrine\ \(0\)\
\-\ enlargement\\ of\\ the\\ inferior\\,\\ medial\\ and\\ superior\\ recti\\ with\\ sparing\\ of\\ the\\ tendons\\.\\ \\ symmetric\\ bilateral\\ prominent\\ proptosis\\.\\ \\ optic\\ nerves\\ are\\ normal\\.\\ \\ no\\ retrobulbar\\ mass\\ or\\ fatty\\ infiltration\\.\\ \\ prominent\\ maxillary\\ sinus\\ mucosal\\ thickening\\ with\\ extension\\ into\\ the\\ ethmoid\\ air\\ cells\\ and\\ frontal\\ sinuses\\ with\\ obstruction\\ of\\ the\\ infundibula\\.\ \(0\)\
\-\ graves\\ ophthalmopathy\ \(0\)\
\-\ thyroid\\ opthalmopathy\\,\\ acromegaly\\,\\ pseudotumor\\,\\ infection\\,\\ plasma\\ cell\\ granuloma\\,\\ sarcoid\\,\\ tb\\,\\ lymphoma\\,\\ leukemia\\,\\ rhabdomyosarcoma\\,\\ metastatic\\,\\ carotid\\ cavernous\\ fistula\\,\\ extradural\\ arteriovenous\\ fistula\\,\\ amyloid\ \(0\)\
\-\ painless\\ proptosis\ \(4\)\
\-\ top\\ considerations\\ being\\ pseudotumor\\ and\\ graves\\.\ \(0\)\
\-\ orbital\\ pseudotumor\\:\\ unilateral\\ 85\\%\\,\\ involves\\ tendon\\,\\ ill\\ defined\\ margins\\,\\ inflammation\\ of\\ fat\\,\\ enlarged\\ lacrimal\\ gland\\,\\ good\\ response\\ to\\ steroids\\,\\ painful\\ and\\ therefore\\ not\\ the\\ diagnosis\\.\ \(0\)\
\-\ graves\\ disease\\:\\ \ \(0\)\
\-\ graves\\‚\\Ä\\ô\\ ophthalmopathy\\ develops\\ in\\ most\\ patients\\ with\\ graves\\‚\\Ä\\ô\\ disease\\,\\ and\\ is\\ the\\ most\\ common\\ orbital\\ disorder\\ in\\ us\\ population\\ causing\\ most\\ unilateral\\ and\\ bilateral\\ exophthalmos\\ in\\ adults\\,\\ 80\\%\\ of\\ bilateral\\,\\ 15\\-28\\%\\ of\\ unilateral\\ cases\\.\\ orbital\\ disease\\ usually\\ follows\\ hormonal\\ changes\\ but\\ may\\ be\\ first\\ sign\\ of\\ graves\\.\\ \\ it\\ is\\ more\\ common\\ in\\ females\\ but\\ worse\\ clinical\\ course\\ in\\ males\\ and\\ older\\ age\\.\ \(0\)\
\-\ painless\\ proptosis\\;\\ double\\ vision\\,\\ and\\ periorbital\\ swelling\\ and\\ chemosis\\ are\\ common\\.\ \(0\)\
\-\ werner\\‚\\Ä\\ôs\\ modified\\ staging\\ system\\ for\\ thyroid\\ orbitopathy\ \(0\)\
\-\ \\‚\\Ä\\¢\\	grade1\\:\\ asymptomatic\\,\\ lid\\ retraction\\,\\ stare\\,\\ lid\\ lag\\ \\(spasm\\ of\\ upper\\ lid\\ due\\ to\\ thyrotoxicosis\\)\ \(0\)\
\-\ \\‚\\Ä\\¢\\	grade\\ 2\\:\\ symptomatic\\ eyelid\\ retraction\\,\\ soft\\ tissue\\ involvement\ \(0\)\
\-\ \\‚\\Ä\\¢\\	grade\\ 3\\:\\ proptosis\\ as\\ determined\\ by\\ exophthalmometer\\ measurement\\ \\>22mm\\,\\ without\\ diplopia\ \(0\)\
\-\ \\‚\\Ä\\¢\\	grade\\ 4\\:\\ proptosis\\ \\>\\ 22mm\\ with\\ diplopia\\,\\ extraocular\\ muscle\\ involvement\\;\\ affects\\ muscles\\ at\\ midpoint\ \(0\)\
\-\ \\‚\\Ä\\¢\\	grade\\ 5\\:\\ corneal\\ involvement\\ \\(ulceration\\)\ \(0\)\
\-\ \\‚\\Ä\\¢\\	grade\\ 6\\:\\ optic\\ nerve\\ involvement\\:\\ loss\\ of\\ vision\ \(0\)\
\-\ it\\ resolves\\ spontaneously\\ in\\ more\\ than\\ 90\\%\\ of\\ cases\\ with\\ the\\ remaining\\ developing\\ eye\\ complications\\.\\ \\ treatment\\:\\ head\\ elevation\\ at\\ night\\,\\ lubricating\\ eyedrops\\,\\ ointments\\&\\#8594\\;\\ steroids\\/radiation\\ therapy\\ \\&\\#8594\\;\\ immunosuppressives\\,\\ surgery\\.\\ \ \(0\)\
\-\ pathophysiology\\:\\ enlargement\\ of\\ eom\\:\\ 3\\ basic\\ mechanisms\\:\\ infiltration\\ by\\ abnormal\\ cells\\,\\ deposition\\ of\\ abnormal\\ material\\ \\(amyloid\\,\\ mucopolysaccharides\\)\\,\\ or\\ edema\\ from\\ vascular\\ congestion\\.\\ degree\\ of\\ orbital\\ involvement\\ does\\ not\\ correlate\\ with\\ degree\\ of\\ thyroid\\ dysfunction\\ or\\ levels\\ of\\ circulating\\ autoantibodies\\.\ \(0\)\
\-\ \\	inflammatory\\ leukocytic\\ infiltration\\ with\\ edema\\ and\\ deposition\\ of\\ mucopolysaccharides\\ in\\ the\\ orbital\\ contents\\,\\ predominantly\\ involving\\ the\\ eoms\\ and\\ retrobulbar\\ fat\\.\\ \\ thought\\ to\\ be\\ autoimmune\\ due\\ to\\ cross\\-reactivity\\ between\\ eye\\ muscle\\ and\\ thyroid\\ autoantigens\\.\\ \\ autoantibodies\\ implicated\\ include\\:\\ long\\ acting\\ thyroid\\ stimulating\\ factor\\ \\(lats\\)\\ and\\ thyroid\\ stimulating\\ immunoglobulins\\ \\(tsi\\)\\,\\ and\\ circulating\\ autoantibodies\\ against\\ a\\ human\\ eye\\ muscle\\ soluble\\ antigen\\.\ \(0\)\
\-\ \\	early\\ acute\\ inflammatory\\ stage\\ involves\\ deposition\\ of\\ hygroscopic\\ mucopolysaccharides\\ and\\ glycoproteins\\ with\\ infiltration\\ by\\ inflammatory\\ cells\\.\\ \\ \ \(0\)\
\-\ \\	disease\\ progression\\ results\\ in\\ replacement\\ by\\ collagenous\\ tissue\\,\\ necrosis\\ of\\ muscle\\ fibers\\ and\\ fatty\\ degeneration\\,\\ which\\ results\\ from\\ chronic\\ increase\\ in\\ orbital\\ pressure\\ leading\\ to\\ ischemia\\,\\ edema\\,\\ and\\ fibrosis\\ of\\ muscles\\.\\ \\ the\\ fibrotic\\ phase\\ is\\ irreversible\\.\\ \\ \ \(0\)\
\-\ \\	proptosis\\:\\ enlargement\\ of\\ eoms\\,\\ edema\\,\\ increased\\ volume\\ of\\ retrobulbar\\ fat\\,\\ vascular\\ congestion\\,\\ and\\ corneal\\ ulcers\\.\\ degree\\ of\\ proptosis\\ is\\ measured\\ in\\ axial\\ plane\\ at\\ level\\ of\\ lens\\ from\\ interzygomatic\\ line\\ to\\ anterior\\ margin\\ of\\ globe\\.\ \(0\)\
\-\ \\	compression\\ on\\ optic\\ nerve\\ may\\ result\\ in\\ ischemia\\ and\\ optic\\ neuropathy\\.\ \(0\)\
\-\ imaging\\:\ \(4\)\
\-\ muscle\\ involvement\\:\\ most\\ common\\ structures\\ affected\\,\\ most\\ often\\ affects\\ the\\ medial\\ and\\ inferior\\ recti\\ \\‚\\Ä\\úi\\‚\\Ä\\ôm\\ slow\\‚\\Ä\\ù\\ normal\\ recti\\ muscle\\ belly\\ diameter\\ is\\ 3\\ mm\\.\\ often\\ bilateral\\,\\ symmetrical\\ 85\\%\\.\\ isolated\\ involvement\\ of\\ single\\ muscle\\ 10\\%\\ usually\\ superior\\ rectus\\ and\\ levator\\ palpebrae\\ complex\\.\\ classically\\ swelling\\ is\\ maximal\\ in\\ belly\\,\\ sparing\\ tendinous\\ attachments\\,\\ and\\ margins\\ of\\ muscles\\ are\\ smooth\\.\\ \\ \ \(0\)\
\-\ other\\ imaging\\ findings\\ are\\ increased\\ amount\\ of\\ retro\\-ocular\\ fat\\,\\ stranding\\ of\\ the\\ intraconal\\ fat\\,\\ enlarged\\ lacrimal\\ gland\\,\\ stretching\\ of\\ the\\ optic\\ nerve\\,\\ and\\ increased\\ diameter\\ of\\ optic\\ nerve\\ sheath\\ due\\ to\\ csf\\ trapping\\ in\\ subarachnoid\\ space\\.\ \(0\)\
\-\ mr\\:\\ muscles\\ may\\ be\\ thick\\ and\\ of\\ high\\ signal\\ intensity\\ on\\ t2wi\\,\\ reflecting\\ edema\\.\\ \\ tram\\ track\\ sign\\ on\\ t2w\\ is\\ suspicious\\ for\\ optic\\ nerve\\ compression\\ and\\ represents\\ dilatation\\ of\\ subarachnoid\\ space\\ surrounding\\ the\\ optic\\ nerve\\ \\(ddx\\ for\\ this\\ sign\\:\\ increased\\ intracranial\\ pressure\\ and\\ pseudotumor\\ cerebri\\)\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ proptosis\\:\\ 0\\.22005970705052552\ \(0\)\
\-\ optic\\:\\ 0\\.21457860994370898\ \(0\)\
\-\ graves\\:\\ 0\\.20612670902644406\ \(0\)\
\-\ of\\:\\ 0\\.19512749688848477\ \(0\)\
\-\ and\\:\\ 0\\.16740580716866646\ \(0\)\
\-\ orbital\\:\\ 0\\.16398491755293076\ \(0\)\
\-\ involvement\\:\\ 0\\.1578667771026173\ \(0\)\
\-\ muscle\\:\\ 0\\.15487607946782422\ \(0\)\
\-\ thyroid\\:\\ 0\\.14692484041657422\ \(0\)\
\-\ recti\\:\\ 0\\.14284705483915983\ \(0\)\
\-\ mucopolysaccharides\\:\\ 0\\.14284705483915983\ \(0\)\
\-\ autoantibodies\\:\\ 0\\.14284705483915983\ \(0\)\
\-\ nerve\\:\\ 0\\.133373238065841\ \(0\)\
\-\ pseudotumor\\:\\ 0\\.12943271547454774\ \(0\)\
\-\ retrobulbar\\:\\ 0\\.1248440092928423\ \(0\)\
\-\ infiltration\\:\\ 0\\.1229252003552345\ \(0\)\
\-\ lid\\:\\ 0\\.11541547202518201\ \(0\)\
\-\ grade\\:\\ 0\\.11203118962231697\ \(0\)\
\-\ muscles\\:\\ 0\\.10680907821937437\ \(0\)\
\-\ in\\:\\ 0\\.10076844718961128\ \(0\)\
\-\ 22mm\\:\\ 0\\.09966096219693565\ \(0\)\
\-\ 8594\\:\\ 0\\.09966096219693565\ \(0\)\
\-\ fat\\:\\ 0\\.0969149909278373\ \(0\)\
\-\ deposition\\:\\ 0\\.09431130302165379\ \(0\)\
\-\ edema\\:\\ 0\\.09292041094849217\ \(0\)\
\-\ tsi\\:\\ 0\\.08965074357856224\ \(0\)\
\-\ eoms\\:\\ 0\\.087658931832724\ \(0\)\
\-\ the\\:\\ 0\\.08704369137916301\ \(0\)\
\-\ unilateral\\:\\ 0\\.08554951181018221\ \(0\)\
\-\ circulating\\:\\ 0\\.08451608607683722\ \(0\)\
\-\ degree\\:\\ 0\\.08172814533257547\ \(0\)\
\-\ most\\:\\ 0\\.0810811789158385\ \(0\)\
\-\ stimulating\\:\\ 0\\.08008649377267478\ \(0\)\
\-\ corneal\\:\\ 0\\.07921204969641547\ \(0\)\
\-\ ophthalmopathy\\:\\ 0\\.07840244093708015\ \(0\)\
\-\ belly\\:\\ 0\\.07840244093708015\ \(0\)\
\-\ eye\\:\\ 0\\.07478068470337926\ \(0\)\
\-\ lacrimal\\:\\ 0\\.0739728486329177\ \(0\)\
\-\ cells\\:\\ 0\\.07202336916839387\ \(0\)\
\-\ enlargement\\:\\ 0\\.07166477546671646\ \(0\)\
\-\ common\\:\\ 0\\.07068353583309604\ \(0\)\
\-\ amyloid\\:\\ 0\\.07044664007448508\ \(0\)\
\-\ retraction\\:\\ 0\\.06937120995673879\ \(0\)\
\-\ increased\\:\\ 0\\.06739784004933821\ \(0\)\
\-\ bilateral\\:\\ 0\\.066984599595928\ \(0\)\
\-\ sparing\\:\\ 0\\.06540656947389886\ \(0\)\
\-\ diplopia\\:\\ 0\\.06517162022861606\ \(0\)\
\-\ sign\\:\\ 0\\.06471582925600801\ \(0\)\
\-\ affects\\:\\ 0\\.0638590774019161\ \(0\)\
\-\ inflammatory\\:\\ 0\\.06320892866422763\ \(0\)\
\-\ congestion\\:\\ 0\\.06162939301799284\ \(0\)\
\-\ is\\:\\ 0\\.05973227443914076\ \(0\)\
\-\ fatty\\:\\ 0\\.059225278800138205\ \(0\)\
\-\ painless\\:\\ 0\\.057716025195044235\ \(0\)\
\-\ 85\\:\\ 0\\.057483575599431805\ \(0\)\
\-\ fistula\\:\\ 0\\.056286639341866875\ \(0\)\
\-\ subarachnoid\\:\\ 0\\.056082433044251444\ \(0\)\
\-\ with\\:\\ 0\\.05491239905288794\ \(0\)\
\-\ steroids\\:\\ 0\\.054750821057819504\ \(0\)\
\-\ to\\:\\ 0\\.054528321387033334\ \(0\)\
\-\ involves\\:\\ 0\\.05422633383664037\ \(0\)\
\-\ vision\\:\\ 0\\.05397324022771709\ \(0\)\
\-\ ischemia\\:\\ 0\\.05397324022771709\ \(0\)\
\-\ due\\:\\ 0\\.05373282364689684\ \(0\)\
\-\ margins\\:\\ 0\\.0531695898644044\ \(0\)\
\-\ by\\:\\ 0\\.052928159322295165\ \(0\)\
\-\ disease\\:\\ 0\\.052318244640105906\ \(0\)\
\-\ gland\\:\\ 0\\.05062387189755261\ \(0\)\
\-\ diameter\\:\\ 0\\.05008500941375716\ \(0\)\
\-\ thyrotro\\:\\ 0\\.04983048109846783\ \(0\)\
\-\ bn\\:\\ 0\\.04983048109846783\ \(0\)\
\-\ werner\\:\\ 0\\.04983048109846783\ \(0\)\
\-\ grade1\\:\\ 0\\.04983048109846783\ \(0\)\
\-\ exophthalmometer\\:\\ 0\\.04983048109846783\ \(0\)\
\-\ lubricating\\:\\ 0\\.04983048109846783\ \(0\)\
\-\ eyedrops\\:\\ 0\\.04983048109846783\ \(0\)\
\-\ ointments\\:\\ 0\\.04983048109846783\ \(0\)\
\-\ leukocytic\\:\\ 0\\.04983048109846783\ \(0\)\
\-\ autoantigens\\:\\ 0\\.04983048109846783\ \(0\)\
\-\ lats\\:\\ 0\\.04983048109846783\ \(0\)\
\-\ hygroscopic\\:\\ 0\\.04983048109846783\ \(0\)\
\-\ interzygomatic\\:\\ 0\\.04983048109846783\ \(0\)\
\-\ prominent\\:\\ 0\\.04908101287009929\ \(0\)\
\-\ results\\:\\ 0\\.04856068982615245\ \(0\)\
\-\ inh\\:\\ 0\\.047615684946386606\ \(0\)\
\-\ infundibula\\:\\ 0\\.047615684946386606\ \(0\)\
\-\ immunosuppressives\\:\\ 0\\.047615684946386606\ \(0\)\
\-\ glycoproteins\\:\\ 0\\.047615684946386606\ \(0\)\
\-\ palpebrae\\:\\ 0\\.047615684946386606\ \(0\)\
\-\ pressure\\:\\ 0\\.04745038174895918\ \(0\)\
\-\ are\\:\\ 0\\.047294127103691165\ \(0\)\
\-\ may\\:\\ 0\\.047041005119177116\ \(0\)\
\-\ opthalmopathy\\:\\ 0\\.04604426206844322\ \(0\)\
\-\ stare\\:\\ 0\\.04604426206844322\ \(0\)\
\-\ collagenous\\:\\ 0\\.04604426206844322\ \(0\)\
\-\ compression\\:\\ 0\\.045635960793077836\ \(0\)\
\-\ 279\\:\\ 0\\.043829465916362\ \(0\)\
\-\ midpoint\\:\\ 0\\.043829465916362\ \(0\)\
\-\ attachments\\:\\ 0\\.043829465916362\ \(0\)\
\-\ orbitopathy\\:\\ 0\\.042987439498564685\ \(0\)\
\-\ acting\\:\\ 0\\.042987439498564685\ \(0\)\
\-\ enlarged\\:\\ 0\\.042483399857505315\ \(0\)\
\-\ inferior\\:\\ 0\\.04239634984444516\ \(0\)\
\-\ immunoglobulins\\:\\ 0\\.04225804303841861\ \(0\)\
\-\ lens\\:\\ 0\\.04225804303841861\ \(0\)\
\-\ reflecting\\:\\ 0\\.04225804303841861\ \(0\)\
\-\ swelling\\:\\ 0\\.041943446903616816\ \(0\)\
\-\ cases\\:\\ 0\\.04191575431886043\ \(0\)\
\-\ eom\\:\\ 0\\.04161466976428077\ \(0\)\
\-\ irreversible\\:\\ 0\\.04161466976428077\ \(0\)\
\-\ levator\\:\\ 0\\.04161466976428077\ \(0\)\
\-\ space\\:\\ 0\\.041481961596312504\ \(0\)\
\-\ vascular\\:\\ 0\\.04114176322176845\ \(0\)\
\-\ often\\:\\ 0\\.04066286380759865\ \(0\)\
\-\ medial\\:\\ 0\\.040564663426516344\ \(0\)\
\-\ acromegaly\\:\\ 0\\.04051853430093907\ \(0\)\
\-\ implicated\\:\\ 0\\.04051853430093907\ \(0\)\
\-\ tendinous\\:\\ 0\\.04051853430093907\ \(0\)\
\-\ superior\\:\\ 0\\.04051589227928097\ \(0\)\
\-\ chemosis\\:\\ 0\\.04004324688633739\ \(0\)\
\-\ soluble\\:\\ 0\\.04004324688633739\ \(0\)\
\-\ lag\\:\\ 0\\.03960602484820774\ \(0\)\
\-\ intraconal\\:\\ 0\\.03960602484820774\ \(0\)\
\-\ tram\\:\\ 0\\.03960602484820774\ \(0\)\
\-\ usually\\:\\ 0\\.039231849534715826\ \(0\)\
\-\ exophthalmos\\:\\ 0\\.03920122046854008\ \(0\)\
\-\ resolves\\:\\ 0\\.03920122046854008\ \(0\)\
\-\ thyrotoxicosis\\:\\ 0\\.03882435660717529\ \(0\)\
\-\ hormonal\\:\\ 0\\.038471824008394\ \(0\)\
\-\ fibrotic\\:\\ 0\\.038471824008394\ \(0\)\
\-\ eyelid\\:\\ 0\\.03814067053443195\ \(0\)\
\-\ human\\:\\ 0\\.03814067053443195\ \(0\)\
\-\ antigen\\:\\ 0\\.03814067053443195\ \(0\)\
\-\ stretching\\:\\ 0\\.03814067053443195\ \(0\)\
\-\ be\\:\\ 0\\.03792022948367902\ \(0\)\
\-\ abnormal\\:\\ 0\\.03744016313058576\ \(0\)\
\-\ from\\:\\ 0\\.03712544169221953\ \(0\)\
\-\ mechanisms\\:\\ 0\\.03698642431645885\ \(0\)\
\-\ pathophysiology\\:\\ 0\\.03648950376697404\ \(0\)\
\-\ ft4\\:\\ 0\\.036257027856312775\ \(0\)\
\-\ plasma\\:\\ 0\\.036257027856312775\ \(0\)\
\-\ periorbital\\:\\ 0\\.036257027856312775\ \(0\)\
\-\ modified\\:\\ 0\\.036257027856312775\ \(0\)\
\-\ cerebri\\:\\ 0\\.03603404345006981\ \(0\)\
\-\ extradural\\:\\ 0\\.03581980581818313\ \(0\)\
\-\ measurement\\:\\ 0\\.03581980581818313\ \(0\)\
\-\ maximal\\:\\ 0\\.03561365458217494\ \(0\)\
\-\ trapping\\:\\ 0\\.03541500143851547\ \(0\)\
\-\ at\\:\\ 0\\.035307769931687286\ \(0\)\
\-\ symmetrical\\:\\ 0\\.03522332003724254\ \(0\)\
\-\ basic\\:\\ 0\\.03503813757715068\ \(0\)\
\-\ autoimmune\\:\\ 0\\.03485902777962795\ \(0\)\
\-\ track\\:\\ 0\\.034685604978369394\ \(0\)\
\-\ 125\\:\\ 0\\.03451751911883324\ \(0\)\
\-\ correlate\\:\\ 0\\.03435445150440734\ \(0\)\
\-\ more\\:\\ 0\\.03421956104049508\ \(0\)\
\-\ ulceration\\:\\ 0\\.034042231704231554\ \(0\)\
\-\ neuropathy\\:\\ 0\\.034042231704231554\ \(0\)\
\-\ endocrine\\:\\ 0\\.033892568659522365\ \(0\)\
\-\ extraocular\\:\\ 0\\.033892568659522365\ \(0\)\
\-\ tendons\\:\\ 0\\.0336050096661019\ \(0\)\
\-\ develops\\:\\ 0\\.0336050096661019\ \(0\)\
\-\ t2wi\\:\\ 0\\.033331834774260966\ \(0\)\
\-\ ulcers\\:\\ 0\\.03282334142506945\ \(0\)\
\-\ imaging\\:\\ 0\\.03275051818778254\ \(0\)\
\-\ tissue\\:\\ 0\\.0326909178280841\ \(0\)\
\-\ ethmoid\\:\\ 0\\.03258581011430803\ \(0\)\
\-\ classically\\:\\ 0\\.03258581011430803\ \(0\)\
\-\ or\\:\\ 0\\.032519281896558026\ \(0\)\
\-\ globe\\:\\ 0\\.03247080882628817\ \(0\)\
\-\ considerations\\:\\ 0\\.0322478244200452\ \(0\)\
\-\ rectus\\:\\ 0\\.0322478244200452\ \(0\)\
\-\ males\\:\\ 0\\.032139655352326116\ \(0\)\
\-\ it\\:\\ 0\\.03190000559718661\ \(0\)\
\-\ staging\\:\\ 0\\.031827435552150334\ \(0\)\
\-\ spontaneously\\:\\ 0\\.031727205961727754\ \(0\)\
\-\ rhabdomyosarcoma\\:\\ 0\\.031532100956821386\ \(0\)\
\-\ spasm\\:\\ 0\\.031532100956821386\ \(0\)\
\-\ against\\:\\ 0\\.031532100956821386\ \(0\)\
\-\ fibers\\:\\ 0\\.031532100956821386\ \(0\)\
\-\ plane\\:\\ 0\\.03143710100721793\ \(0\)\
\-\ t2w\\:\\ 0\\.03143710100721793\ \(0\)\
\-\ females\\:\\ 0\\.03134372506815664\ \(0\)\
\-\ contents\\:\\ 0\\.03116162955893436\ \(0\)\
\-\ sheath\\:\\ 0\\.030985409134353017\ \(0\)\
\-\ maxillary\\:\\ 0\\.030899385948344786\ \(0\)\
\-\ but\\:\\ 0\\.030816630857060528\ \(0\)\
\-\ measured\\:\\ 0\\.030731300088808627\ \(0\)\
\-\ follows\\:\\ 0\\.0304884885848682\ \(0\)\
\-\ top\\:\\ 0\\.030409892129328764\ \(0\)\
\-\ dysfunction\\:\\ 0\\.03025601267420695\ \(0\)\
\-\ tsh\\:\\ 0\\.030106349629497757\ \(0\)\
\-\ slow\\:\\ 0\\.03003302826796397\ \(0\)\
\-\ arteriovenous\\:\\ 0\\.029889273671011317\ \(0\)\
\-\ developing\\:\\ 0\\.029818790636077296\ \(0\)\
\-\ determined\\:\\ 0\\.02968049566918269\ \(0\)\
\-\ remaining\\:\\ 0\\.029612639400069102\ \(0\)\
\-\ isolated\\:\\ 0\\.029612639400069102\ \(0\)\
\-\ thick\\:\\ 0\\.029612639400069102\ \(0\)\
\-\ ddx\\:\\ 0\\.029612639400069102\ \(0\)\
\-\ population\\:\\ 0\\.029479404516369455\ \(0\)\
\-\ ill\\:\\ 0\\.029413986256409636\ \(0\)\
\-\ mucosal\\:\\ 0\\.029349342195220635\ \(0\)\
\-\ sinuses\\:\\ 0\\.029349342195220635\ \(0\)\
\-\ sarcoid\\:\\ 0\\.02922230485513671\ \(0\)\
\-\ factor\\:\\ 0\\.02922230485513671\ \(0\)\
\-\ nerves\\:\\ 0\\.029098154978800913\ \(0\)\
\-\ adults\\:\\ 0\\.029098154978800913\ \(0\)\
\-\ degeneration\\:\\ 0\\.028976764218279983\ \(0\)\
\-\ older\\:\\ 0\\.02891706570692482\ \(0\)\
\-\ response\\:\\ 0\\.028741787799715902\ \(0\)\
\-\ progression\\:\\ 0\\.028571959838612326\ \(0\)\
\-\ leukemia\\:\\ 0\\.02846160539002059\ \(0\)\
\-\ elevation\\:\\ 0\\.02840725310656923\ \(0\)\
\-\ for\\:\\ 0\\.028332420999283525\ \(0\)\
\-\ on\\:\\ 0\\.028231917291085772\ \(0\)\
\-\ granuloma\\:\\ 0\\.028195095977247536\ \(0\)\
\-\ night\\:\\ 0\\.027990871839307783\ \(0\)\
\-\ replacement\\:\\ 0\\.027990871839307783\ \(0\)\
\-\ stranding\\:\\ 0\\.02789155347741653\ \(0\)\
\-\ suspicious\\:\\ 0\\.027842563378466252\ \(0\)\
\-\ represents\\:\\ 0\\.027842563378466252\ \(0\)\
\-\ tb\\:\\ 0\\.027745881926796778\ \(0\)\
\-\ leading\\:\\ 0\\.02769817542776272\ \(0\)\
\-\ painful\\:\\ 0\\.027557506038132035\ \(0\)\
\-\ therefore\\:\\ 0\\.027465699517101462\ \(0\)\
\-\ double\\:\\ 0\\.027465699517101462\ \(0\)\
\-\ volume\\:\\ 0\\.027375410528909752\ \(0\)\
\-\ margin\\:\\ 0\\.027330819592155126\ \(0\)\
\-\ predominantly\\:\\ 0\\.027286589719578733\ \(0\)\
\-\ tendon\\:\\ 0\\.027199190104328412\ \(0\)\
\-\ cavernous\\:\\ 0\\.027028477478971816\ \(0\)\
\-\ thought\\:\\ 0\\.026903855508999465\ \(0\)\
\-\ symmetric\\:\\ 0\\.026702269554843592\ \(0\)\
\-\ phase\\:\\ 0\\.026662829965322894\ \(0\)\
\-\ disorder\\:\\ 0\\.0263571636865311\ \(0\)\
\-\ carotid\\:\\ 0\\.026246809237939362\ \(0\)\
\-\ material\\:\\ 0\\.026246809237939362\ \(0\)\
\-\ worse\\:\\ 0\\.02610305464098671\ \(0\)\
\-\ fibrosis\\:\\ 0\\.02610305464098671\ \(0\)\
\-\ per\\:\\ 0\\.02586024313704628\ \(0\)\
\-\ smooth\\:\\ 0\\.025726190779621926\ \(0\)\
\-\ affected\\:\\ 0\\.025627767226385028\ \(0\)\
\-\ causing\\:\\ 0\\.02559534956792304\ \(0\)\
\-\ normal\\:\\ 0\\.02544425477204659\ \(0\)\
\-\ dilatation\\:\\ 0\\.025436085825112097\ \(0\)\
\-\ good\\:\\ 0\\.02534270988605081\ \(0\)\
\-\ intracranial\\:\\ 0\\.02507179356749751\ \(0\)\
\-\ inflammation\\:\\ 0\\.02504250470687858\ \(0\)\
\-\ increase\\:\\ 0\\.025013372054258815\ \(0\)\
\-\ amount\\:\\ 0\\.024926894901126418\ \(0\)\
\-\ 90\\:\\ 0\\.024898370766238954\ \(0\)\
\-\ stage\\:\\ 0\\.024813681326890585\ \(0\)\
\-\ us\\:\\ 0\\.024785740808587718\ \(0\)\
\-\ levels\\:\\ 0\\.02470276666503562\ \(0\)\
\-\ csf\\:\\ 0\\.02462103407654462\ \(0\)\
\-\ not\\:\\ 0\\.024601889520153117\ \(0\)\
\-\ 80\\:\\ 0\\.024305810504273166\ \(0\)\
\-\ 16\\:\\ 0\\.024280344913076225\ \(0\)\
\-\ line\\:\\ 0\\.024280344913076225\ \(0\)\
\-\ complex\\:\\ 0\\.02400778972279796\ \(0\)\
\-\ symptomatic\\:\\ 0\\.02395966289677217\ \(0\)\
\-\ single\\:\\ 0\\.02395966289677217\ \(0\)\
\-\ complications\\:\\ 0\\.023864662947168717\ \(0\)\
\-\ necrosis\\:\\ 0\\.023817775453971464\ \(0\)\
\-\ system\\:\\ 0\\.023771287008107427\ \(0\)\
\-\ structures\\:\\ 0\\.023412971074303804\ \(0\)\
\-\ result\\:\\ 0\\.023326947888295577\ \(0\)\
\-\ course\\:\\ 0\\.023015913624623262\ \(0\)\
\-\ sinus\\:\\ 0\\.022515488754621567\ \(0\)\
\-\ early\\:\\ 0\\.022460590207914754\ \(0\)\
\-\ mm\\:\\ 0\\.02229912940609593\ \(0\)\
\-\ defined\\:\\ 0\\.022228873010973496\ \(0\)\
\-\ intensity\\:\\ 0\\.022125154209689177\ \(0\)\
\-\ extension\\:\\ 0\\.02205708654486673\ \(0\)\
\-\ obstruction\\:\\ 0\\.021825315318386076\ \(0\)\
\-\ involving\\:\\ 0\\.021825315318386076\ \(0\)\
\-\ being\\:\\ 0\\.02171301616221372\ \(0\)\
\-\ does\\:\\ 0\\.02154108221557348\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.021212644756957843\ \(0\)\
\-\ thickening\\:\\ 0\\.02119817492222258\ \(0\)\
\-\ first\\:\\ 0\\.021027462296865983\ \(0\)\
\-\ surrounding\\:\\ 0\\.02078099826225229\ \(0\)\
\-\ long\\:\\ 0\\.02066181478321706\ \(0\)\
\-\ air\\:\\ 0\\.020380977453621878\ \(0\)\
\-\ between\\:\\ 0\\.02024579405583353\ \(0\)\
\-\ mr\\:\\ 0\\.020161478123915878\ \(0\)\
\-\ frontal\\:\\ 0\\.020054949861921936\ \(0\)\
\-\ clinical\\:\\ 0\\.019747290443182054\ \(0\)\
\-\ age\\:\\ 0\\.01956210798309019\ \(0\)\
\-\ loss\\:\\ 0\\.018983378770141352\ \(0\)\
\-\ changes\\:\\ 0\\.01883137287340468\ \(0\)\
\-\ infection\\:\\ 0\\.01882201150107342\ \(0\)\
\-\ level\\:\\ 0\\.01882201150107342\ \(0\)\
\-\ head\\:\\ 0\\.018584082189698436\ \(0\)\
\-\ lymphoma\\:\\ 0\\.018557283970364227\ \(0\)\
\-\ include\\:\\ 0\\.018539491252943813\ \(0\)\
\-\ chronic\\:\\ 0\\.018495261380367417\ \(0\)\
\-\ 10\\:\\ 0\\.018220367684415904\ \(0\)\
\-\ axial\\:\\ 0\\.017998723898971985\ \(0\)\
\-\ therapy\\:\\ 0\\.017903030483737932\ \(0\)\
\-\ cell\\:\\ 0\\.017824546958028622\ \(0\)\
\-\ high\\:\\ 0\\.017708896355366887\ \(0\)\
\-\ than\\:\\ 0\\.017663313119337394\ \(0\)\
\-\ signal\\:\\ 0\\.017663313119337394\ \(0\)\
\-\ patients\\:\\ 0\\.017528802260261832\ \(0\)\
\-\ anterior\\:\\ 0\\.0173975242869253\ \(0\)\
\-\ metastatic\\:\\ 0\\.017089309442877558\ \(0\)\
\-\ acute\\:\\ 0\\.01685598223331045\ \(0\)\
\-\ surgery\\:\\ 0\\.01675254985216678\ \(0\)\
\-\ upper\\:\\ 0\\.01665103967108816\ \(0\)\
\-\ soft\\:\\ 0\\.016588540597748492\ \(0\)\
\-\ into\\:\\ 0\\.016563739831337982\ \(0\)\
\-\ without\\:\\ 0\\.016435351662748742\ \(0\)\
\-\ other\\:\\ 0\\.016181517280154423\ \(0\)\
\-\ diagnosis\\:\\ 0\\.016152752814430373\ \(0\)\
\-\ findings\\:\\ 0\\.015378357257906511\ \(0\)\
\-\ treatment\\:\\ 0\\.014842821104149778\ \(0\)\
\-\ which\\:\\ 0\\.01416843719055229\ \(0\)\
\-\ as\\:\\ 0\\.01251779088738008\ \(0\)\
\-\ mass\\:\\ 0\\.011902015301632096\ \(0\)\
\-\ this\\:\\ 0\\.010706891670921178\ \(0\)\
\-\ no\\:\\ 0\\.010132645129774805\ \(0\)\
